Pill graphic

This study (A5359) is looking to see if monthly, long-acting injectable HIV medications will be more successful than standard oral HIV medication at controlling the viral load in people who have a hard time taking their pills every day. Extra financial rewards will be used within the first 20 weeks of the study to help motivate participants to stay on their oral HIV medication. If the viral load becomes or stays undetectable, they have a 50/50 chance of receiving either monthly injectable medication or staying on oral medication for 48 weeks. After that, all participants will receive the monthly injectable medication for another 48 weeks


  • ≥ 18 years of age
  • HIV positive
  • Have or had a detectable viral load in the past 12 months

For more information about A5359, please contact our study team at 310-843-2015 or CAREOUTREACH@mednet.ucla.edu